
Arvinas Inc (ARVN) Stock Forecast & Price Target
Arvinas Inc (ARVN) Analyst Ratings
Bulls say
Arvinas is positioned for a meaningful catalyst cycle in 3Q26-2027, with initial ARV-393 monotherapy data expected in 4Q26, a broader update in mid-2027, and additional readouts for ARV-027, ARV-6723, and ARV-102 that could validate its protein-degradation platform across oncology and neurology. The core bullish case is that early clinical evidence could move the story from platform promise to measurable efficacy, especially if ARV-393 shows response rates above 30% in its early T-cell lymphoma cohort, along with supportive safety, PK/PD, and BCL6 degradation signals. While the outlook also reflects a lower $13 valuation versus $18 due to revised launch and regulatory assumptions, the company’s broad pipeline, seven checkpoint-resistant preclinical models, and European-led path for ARV-102 support long-term optionality and make weakness in the shares potentially attractive.
Bears say
Arvinas is facing a weaker fundamental outlook because management has had to reassess launch assumptions across its pipeline, pushing expected cash flows farther into the future and lowering their present value. The decision to seek an out-licensing agreement for additional ARV-806 trials signals capital constraints and a need to reprioritize a program that would require substantial funding to stay competitive, while early monotherapy dose-escalation data remained immature on clinical activity and tolerability. On top of these execution risks, the company still faces meaningful clinical, regulatory, competitive, and financing risk, including the possibility of additional equity financing to support development.
This aggregate rating is based on analysts' research of Arvinas Inc and is not a guaranteed prediction by Public.com or investment advice.
Arvinas Inc (ARVN) Analyst Forecast & Price Prediction
Start investing in Arvinas Inc (ARVN)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Arvinas Inc (ARVN) Forecast
Arvinas Inc (ARVN) Analyst Forecast & Price Prediction
Start investing in Arvinas Inc (ARVN)
Order type
Buy in
Order amount
Est. shares
0 shares